Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention
Pei ZhuZhan GaoXiaofang TangJingjing XuYin ZhangLijian GaoJue ChenShubin QiaoYuejin YangRunlin GaoBo XuJinqing Yuan
15
Citation
25
Reference
10
Related Paper
Citation Trend
Abstract:
Background: Prior studies have reported controversial conclusions regarding the risk of adverse cardiovascular events in patients using proton-pump inhibitors (PPIs) combined with clopidogrel therapy, causing much uncertainty in clinical practice. We sought to evaluate the safety of PPIs use among high-risk cardiovascular patients who underwent percutaneous coronary intervention (PCI) in a long-term follow-up study. Methods: A total of 7868 consecutive patients who had undergone PCI and received dual antiplatelet therapy (DAPT) at a single center from January 2013 to December 2013 were enrolled. Adenosine diphosphate (ADP)-induced platelet aggregation inhibition was measured by modified thromboelastography (mTEG) in 5042 patients. Propensity score matching (PSM) was applied to control differing baseline factors. Cox proportional hazards regression was used to evaluate the 2-year major adverse cardiovascular and cerebrovascular events (MACCEs), as well as individual events, including all-cause death, myocardial infarction, unplanned target vessel revascularization, stent thrombosis, and stroke. Results: Among the whole cohort, 27.2% were prescribed PPIs. The ADP-induced platelet aggregation inhibition by mTEG was significantly lower in PPI users than that in non-PPI users (42.0 ± 30.9% vs. 46.4 ± 31.4%, t = 4.435, P < 0.001). Concomitant PPI use was not associated with increased MACCE through 2-year follow-up (12.7% vs. 12.5%, χ2 = 0.086, P = 0.769). Other endpoints showed no significant differences after multivariate adjustment, regardless of PSM. Conclusion: In this large cohort of real-world patients, the combination of PPIs with DAPT was not associated with increased risk of MACCE in patients who underwent PCI at up to 2 years of follow-up.To assess the application status of transradial coronary angiography (TRA) and transradial coronary intervention (TRI) in China in 2007.From Feb 10th to Apr 30th 2008, investigating questionnaires of this study were sent to 450 hospitals in China to collect information on application of percutaneous coronary intervention (PCI) and TRI in these centers.One hundred and twelve questionnaires were received. A total of 115 142 coronary angiography (CAG) and 48 379 PCI were performed in these centers including 69 354 TRA (60.24%) and 27 227 TRI (56.28%). A total of 77 488 stents were implanted from 47 160 PCI (1.64 stents per PCI) and 93.98% implanted stents were drug-eluting stent. Total 9290 stents (86.95% drug-eluting stent) were implanted in 7140 primary PCI (1.30 stents per PCI).TRA and TRI have become the major approaches of CAG and PCI in China in 2007.
Cite
Citations (0)
Objective To observe the long-term effectiveness and safety of domestic clopidogrel (Talcom) on patients after percutaneous coronary intervention (PCI).Methods A total of 257 patients were randomly divided into two groups after PCI,including domestic clopidogrel group (n=129) and imported clopidogrel (Plavix) group (n=128),300 mg of clopidogrel were given 6 hours prior to PCI respectively followed by 75 mg daily,Major adverse cardiac events (MACE) and adverse effects were observed in 12 months after PCI. Results There was no statistic significance in MACE and adverse effect in 12 months after PCI. Conclusion Domestic clopidogrel may be effective and safe for patients after PCI,which is economic and worthy of further clinical application.
Mace
Loading dose
Cite
Citations (0)
Presentation (obstetrics)
Cite
Citations (0)
Key Points Patients undergoing percutaneous coronary intervention (PCI) in the state of Michigan have more comorbidities compared to patients undergoing PCI in the United Kingdom. While the adoption of radial artery access for PCI has increased steadily over time in both Michigan and the United Kingdom, the use of radial access was significantly greater in the UK at all time points compared to Michigan for all PCI indications. The use of mechanical support during PCI has increased over time in Michigan but decreased over time in the United Kingdom.
Cite
Citations (0)
AIM To examine the platelet aggregation and the prevalence of clopidogrel-resistance among patients undergoing percutaneous coronary intervention (PCI). METHODS Thirty-seven patients with acute coronary symptom (ACS) who underwent PCI were treated with clopidogrel (300 mg,loading dose,followed with 75 mg/d). Platelet aggregation function was assessed before and 2,4,6,24,48 h and 30 d after clopidogrel treatment. RESULTS The ratio of clopidogrel resistance were 62%,46%,32%,38%,49% and 43% at different times,platelet inhibition was much lower in clopidogrel resistants than responders,and subacute in-stent thrombosis occurred in one patient with clopidogrel resistance. CONCLUSION Clopidogrel-resistance may occur in some patients undergoing percutaneous coronary intervention.
Loading dose
Cite
Citations (0)
Background— Radial access for percutaneous coronary intervention (r-PCI) is associated with reduced vascular complications; however, previous reports have shown that <2% of percutaneous coronary intervention (PCI) procedures in the United States are performed via the radial approach. Our aims were to evaluate temporal trends in r-PCI and compare procedural outcomes between r-PCI and transfemoral PCI. Methods and Results— We conducted a retrospective cohort study from the CathPCI registry (n=2 820 874 procedures from 1381 sites) between January 2007 and September 2012. Multivariable logistic regression models were used to evaluate the adjusted association between r-PCI and bleeding, vascular complications, and procedural success, using transfemoral PCI as the reference. Outcomes in high-risk subgroups such as age ≥75 years, women, and patients with acute coronary syndrome were also examined. The proportion of r-PCI procedures increased from 1.2% in quarter 1 2007 to 16.1% in quarter 3 2012 and accounted for 6.3% of total procedures from 2007 to 2012 (n=178 643). After multivariable adjustment, r-PCI use in the studied cohort of patients was associated with lower risk of bleeding (adjusted odds ratio, 0.51; 95% confidence interval, 0.49–0.54) and lower risk of vascular complications (adjusted odds ratio, 0.39; 95% confidence interval, 0.31–0.50) in comparison with transfemoral PCI. The reduction in bleeding and vascular complications was consistent across important subgroups of age, sex, and clinical presentation. Conclusions— There has been increasing adoption of r-PCI in the United States. Transradial PCI now accounts for 1 of 6 PCIs performed in contemporary clinical practice. In comparison with traditional femoral access, transradial PCI is associated with lower vascular and bleeding complication rates.
Cite
Citations (443)
Cite
Citations (9)
Percutaneous coronary intervention (PCI) continues to advance at pace with an ever-broadening indication. In this article we will review the recent technological advances in PCI that have enabled more complex coronary disease to be treated. The choice of revascularisation strategy must take into account the evidence-just because we can treat by PCI does not necessarily mean we should. When PCI is indicated, a safe, precision PCI approach guided by physiology, imaging and optimal lesion preparation should be the goal to obtain complete revascularisation and a durable long-term result. When these standards are adhered to, the outcomes can be excellent, in even complex coronary disease. We provide contemporary trial evidence to justify PCI and treatment algorithms that ensure optimal revascularisation decision making to achieve the best patient outcomes.
Interventional cardiology
Cite
Citations (101)
Background: The use of radial access for percutaneous coronary intervention (r-PCI) is associated with reduced risk of bleeding complications and higher patient satisfaction. However, the use of r-PCI differs greatly by country and is unknown in China. We examined trends in the adoption of r-PCI in China over the past decade and identified factors associated with its use. Methods: We used a two-stage random sampling strategy to create a nationally representative sample of 5,462 patients undergoing percutaneous coronary intervention (PCI) in China in 2001 (n=402; 24 sites), 2006 (n=1,390; 44 sites), and 2011 (n=3,670; 54 sites). We calculated the weighted proportion of patients receiving r-PCI in each time period and conducted multivariable analysis to identify the patient and hospital characteristics associated with not receiving r-PCI in 2011. Results: Among 5,462 patients who underwent PCI, the use of r-PCI increased markedly over time (2001: 3.4% [95% CI 0.0%-8.5%]; 2006: 36.5% [95% CI 34.2%-38.9%], 2011: 74.7% [95% CI 73.9-75.6]; P for trend <0.001). Increases in r-PCI use were widespread, including high-risk subgroups such as the elderly, women, and patients with acute coronary syndromes (Figure). In multivariable analysis of 3,670 patients undergoing PCI in 2011, cardiogenic shock and emergency PCI were strongly associated with failure to use r-PCI in 2011. Conclusion: Over a recent ten-year period, radial access became the predominant strategy for PCI in China, even among high-risk patients. This study demonstrates the responsiveness of the interventional cardiology community to emerging evidence. A deeper understanding of the factors facilitating r-PCI adoption in China may help increase its usage in countries in which r-PCI use remains low.
Cite
Citations (0)